All In Biotech

Drug Trial Radar · NCT02102204

Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis

A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis

Last checked: Nov 20, 2026Latest source record: Nov 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

902

Actual

Start

Mar 25, 2014

Primary completion

Nov 4, 2016

Study completion Jun 26, 2017

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Apr 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 110 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, single-arm, extension study to characterize the long-term safety and tolerability of etelcalcetide in the treatment of Secondary Hyperparathyroidism (SHPT) in adults with Chronic Kidney Disease (CKD) on hemodialysis.

Conditions

  • Hyperparathyroidism, Secondary

Interventions

  • EtelcalcetideDrug

    Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: From the date of first dose of etelcalcetide (in the current study) and up to 30 days after the last dose; median duration of treatment was 563 days.

Locations

228 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Alhambra, California

  • Research Site

    Azusa, California

  • Research Site

    Bakersfield, California

  • Research Site

    Cudahy, California

  • Research Site

    Granada Hills, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Northridge, California

  • Research Site

    Riverside, California

  • Research Site

    Simi Valley, California

  • Research Site

    Vacaville, California

  • Research Site

    Whittier, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Westminster, Colorado

  • Research Site

    Stamford, Connecticut

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Augusta, Georgia

  • Research Site

    Dublin, Georgia

  • Research Site

    Meridian, Idaho

  • Research Site

    Highland Park, Illinois

  • Research Site

    Merrillville, Indiana

  • Research Site

    Michigan City, Indiana

  • Research Site

    Wichita, Kansas

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Springfield, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    Pontiac, Michigan

  • Research Site

    Brookhaven, Mississippi

  • Research Site

    Columbus, Mississippi

  • Research Site

    Gulfport, Mississippi

  • Research Site

    Tupelo, Mississippi

  • Research Site

    Kansas City, Missouri

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Reno, Nevada

  • Research Site

    Eatontown, New Jersey

Showing 40 of 228 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.